Literature DB >> 33608765

Long-term outcome in meningiomas involving the major dural sinuses with combined therapy of subtotal resection and early postoperative gamma knife radiosurgery.

Peng Lv1,2, Jia-Jing Wang1, Nan-Xiang Xiong1, Xiao-Ming Liu3, Dong-Xiao Yao1, Xiao-Bing Jiang1, Hong-Yang Zhao1, Fang-Cheng Zhang4, Peng Fu5.   

Abstract

INTRODUCTION: Total resection of meningiomas involving the major dural sinuses (MIMDS) is still challenging for neurosurgeons. Gamma knife radiosurgery (GKRS) was shown to have a high probability of tumor control. The current study evaluated the clinical outcomes of patients who underwent subtotal resection alone or in combination with postoperative GKRS for the treatment of WHO grade I MIMDS.
METHODS: From January 2006 to December 2016, 204 patients with MIMDS underwent Simpson IV subtotal resection in Wuhan Union Hospital. In 151 patients, no additional treatment was performed, while the tumor remnant was treated with GKRS in 53 patients. All patients were monitored with regular MR follow-ups. We retrospectively reviewed the clinical data, radiological characteristics, and outcomes of these 204 patients. Progression-free survival (PFS) was determined by Kaplan-Meier analysis. Related factors were determined by univariate Cox regression analyses.
RESULTS: The mean follow-up period was 75.5 months. The tumor recurrence/progression rates were 13.9% in the microsurgery group and 3.8% in the combined therapy group (p = 0.045). The 5- and 10- year progression-free survival (PFS) rates were 92.3 and 80.7%, respectively, in the microsurgery group and 100.0 and 88.5% in the combined therapy group. Treatment approach was found to be an independent prognostic factor for tumor recurrence/progression in the univariable analyses (p=0.04).
CONCLUSIONS: Compared with microsurgery alone, targeted Simpson grade IV resection combined with early gamma knife treatment resulted in longer progression-free survival without increased complications for WHO grade I MIMDS.

Entities:  

Keywords:  Gamma knife radiosurgery; Long-term outcome; Meningiomas involving the major dural sinuses; Subtotal resection

Mesh:

Year:  2021        PMID: 33608765     DOI: 10.1007/s00701-021-04766-7

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  21 in total

1.  Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas.

Authors:  Steven J DiBiase; Young Kwok; Susannah Yovino; Cristan Arena; Shahid Naqvi; Richard Temple; William F Regine; Pradip Amin; Chuanfa Guo; Lawrence S Chin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-12-01       Impact factor: 7.038

2.  Gamma Knife radiosurgery for intracranial benign meningiomas: follow-up outcome in 130 patients.

Authors:  Youlin Ge; Dong Liu; Zhiyuan Zhang; Yanhe Li; Yiguang Lin; Guokai Wang; Yongqing Zong; Enhu Liu
Journal:  Neurosurg Focus       Date:  2019-06-01       Impact factor: 4.047

3.  Management of meningiomas invading the major dural venous sinuses: operative technique, results, and potential benefit for higher grade tumors.

Authors:  Alessandra Mantovani; Salvatore Di Maio; Manuel J Ferreira; Laligam N Sekhar
Journal:  World Neurosurg       Date:  2013-07-10       Impact factor: 2.104

4.  Gamma Knife stereotactic radiosurgery for cerebellopontine angle meningioma.

Authors:  Amin Jahanbakhshi; Maziar Azar; Farid Kazemi; Maryam Jalessi; Iran Chanideh; Elahe Amini
Journal:  Clin Neurol Neurosurg       Date:  2019-10-20       Impact factor: 1.876

5.  Adjuvant Radiotherapy Did Not Reduce Recurrence of World Health Organization Grade I Meningiomas with Venous Sinus Involvement: A Propensity Score Adjusted Analysis and Literature Review.

Authors:  Alexandra Gomes Dos Santos; Davi J Fontoura Solla; Ricardo Moscardi; Iuri Santana Neville; Eduardo Weltman; Manoel Jacobsen Teixeira; Wellingson Silva Paiva
Journal:  World Neurosurg       Date:  2019-07-12       Impact factor: 2.104

6.  Treatment of Asymptomatic Meningioma With Gamma Knife Radiosurgery: Long-Term Follow-up With Volumetric Assessment and Clinical Outcome.

Authors:  Amitabh Gupta; Zhiyuan Xu; Or Cohen-Inbar; M Harrison Snyder; Landon K Hobbs; Chelsea Li; Quoc-Tuan Nguyen; Jason P Sheehan
Journal:  Neurosurgery       Date:  2019-11-01       Impact factor: 4.654

7.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

8.  Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.

Authors:  Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

9.  Radiosurgery for parasagittal and parafalcine meningiomas.

Authors:  Dale Ding; Zhiyuan Xu; Ian T McNeill; Chun-Po Yen; Jason P Sheehan
Journal:  J Neurosurg       Date:  2013-08-09       Impact factor: 5.115

Review 10.  Ten-year follow-up after Gamma Knife radiosurgery of meningioma and review of the literature.

Authors:  Bodo E Lippitz; Jiri Bartek; Tiit Mathiesen; Petter Förander
Journal:  Acta Neurochir (Wien)       Date:  2020-06-26       Impact factor: 2.216

View more
  1 in total

1.  Effect of adjuvant radiotherapy after subtotal resection for WHO grade I meningioma: a propensity score matching analysis of the Brain Tumor Registry of Japan.

Authors:  Soichi Oya; Fusao Ikawa; Nao Ichihara; Masahiko Wanibuchi; Yukinori Akiyama; Hirofumi Nakatomi; Nobuhiro Mikuni; Yoshitaka Narita
Journal:  J Neurooncol       Date:  2021-05-17       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.